21.17

0.43% 0.09

After Hours: 21.74 0.57 +2.69%

Kailera Therapeutics Inc (KLRA)

Overview News Price History Discussions Forecast

Kailera Therapeutics Inc stock is traded at $21.17, with a volume of 340.84K. It is up +0.43% in the last 24 hours and down -12.88% over the past month. Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

Previous Close:

$21.08

Open:

$21.2

24h Volume:

340.84K

Relative Volume:

1.26

Market Cap:

$2.74B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.62%

1M Performance:

-12.88%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$20.95

$21.72

1-Week Range:

$19.01

$21.72

52-Week Range:

$19.01

$28.23

Kailera Therapeutics Inc Stock (KLRA) Company Profile

Name

Kailera Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

Address

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

KLRA's Discussions on Twitter

Compare KLRA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KLRA Kailera Therapeutics Inc	21.17	2.73B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Kailera Therapeutics Inc Stock (KLRA) Latest News

May 23, 2026

Meet the new IPO trying to take on Eli Lilly and Novo Nordisk in obesity - MSN

May 23, 2026

May 22, 2026

TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo

May 22, 2026

May 21, 2026

Kailera Therapeutics (KLRA) Insider Trading Activity 2026 $KLRA - MarketBeat

May 21, 2026

Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat

May 21, 2026

May 20, 2026

IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace

May 20, 2026

May 18, 2026

This weight-loss drug challenger could follow Eli Lilly's playbook: Analyst - MSN

May 18, 2026

May 17, 2026

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com

May 17, 2026

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com

May 17, 2026

William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo

May 17, 2026

Kailera Therapeutics IPO: Competing with Eli Lilly and Novo Nordisk in GLP-1 Weight LossNews and Statistics - IndexBox

May 17, 2026

May 16, 2026

RTW Bio NAV Rises 7.0% In April As Biotech IPO And M&A Activity Accelerates - DirectorsTalk Interviews

May 14, 2026

May 13, 2026

Evercore Initiates Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo

May 13, 2026

TD Cowen Initiates Kailera Therapeutics(KLRA.US) With Buy Rating, Announces Target Price $57 - Moomoo

May 13, 2026